Device Trial Radar · NCT05006157
Pericardial Access With ViaOne Device
Last checked: Nov 20, 2026Latest source record: Jan 9, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
10
Planned (sponsor's estimate)
Start
Jul 10, 2021
Primary completion
Jun 30, 2025
Study completion Jun 30, 2025
Sponsor
- Lead sponsor
- CardioViaNot on our public-company list
- Sponsor type
- Industry
- First posted
- Aug 16, 2021
Design
- Study type
- Interventional
- Phase
- Not applicable (typical for device studies)
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated device
- No
- Who can join
- All sexes, from 21 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
ViaOne device is a tool designed to allow percutaneous subxiphoid pericardial access utilizing a proprietary mechanism of entry into the pericardial sac. In this study ViaOne will be used to obtain pericardial access in patients in whom electrophysiological diagnostic (mapping) and/or therapeutic (ablation) of epicardial sites via percutaneous subxiphoid approach to the to the normal, non-distended pericardial space is indicated.
Conditions
- Pericardial Access
Interventions
ViaOne deviceDevice
ViaOne device is designed to allow percutaneous subxiphoid pericardial access utilizing a proprietary mechanism of entry into the pericardial sac.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Safety of ViaOne deviceTime frame: through study completion, an average of 5 days
Locations
4 sites in 2 countries. Site status is shown where the registry gives one.
Hadassah Ein Kerem MC
Jerusalem, Israel
3 more study sites with a free account
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.